Medijski sadržaj
- Tweetovi
- Tweetovi i odgovori
- Medijski sadržaj, trenutna stranica.
-
Simple — yet stunning — graphic to see. # of confirmed cases of coronavirus in China, per daily situation reports from WHO. Just under 25,000 cases if you add suspected cases in China.pic.twitter.com/yHLc9NwMZ0
-
Roche, Illumina have inked a 15-year deal on next-gen sequencing in oncology. Worth remembering Roche walked away from a $6.2B buyout offer for
$ILMN in 2012.#JPM20pic.twitter.com/qJyxUhukBi
-
As 2020 has started out quiet on the M&A front, interesting new research on January's disproportional importance for M&A in biopharma. The month has made up 29% of all deal value, 19% of all deals in typical year from 2015-2019, per Evercore analysts. Jan. deals in last 5 yrs:pic.twitter.com/CyNkrOt0Jt
Prikaži ovu nit -
Great Q - I asked Alnylam's
@JMaraganore a little over a year ago the same thing. He sees it as biotechs take risks, pharmas manage them. For me, I do tend to see it more about size than science. When I think pharma, I think broad commercial portfolios + profitspic.twitter.com/OsvFqkFS63
-
"The three waves of Sangamo" Interesting to see the third wave does not include gene therapy.pic.twitter.com/vaAlFXTqKD
Prikaži ovu nit -
$SGMO unveils 3 new preclinical programs on R&D day, including a PKU gene therapy:pic.twitter.com/DmsIq9JDQL
Prikaži ovu nit -
They say bring the energy, electrify the audience on TV hits My interpretation:pic.twitter.com/AkQkY7LS1G
-
$SNY CEO Paul Hudson will outline plan tomorrow prioritizing these six experimental therapiespic.twitter.com/ag8Goi2lIK
Prikaži ovu nit -
Pharma of the Year:
$AZN Case in point, check out this transformation of their core business over the past few years: https://bit.ly/2Ps3RWf pic.twitter.com/i7T9sgKS7b
Prikaži ovu nit -
Last but not least, well-deserved shout-outs to Industry Dive's UI engineer
@namisumida for designing this series and adding some amazing data visualization and graphic components. And@brian_t_design killed it with custom illustrations for each article, like this one (11/11)pic.twitter.com/GMkfclq7Bi
Prikaži ovu nit -
Acting FDA commissioner Brett Giroir says "hope has never been higher" for SCD community. "The opportunity before us in the coming months and years is profound and historic," Giroir says.pic.twitter.com/QSPMkMzVpV
Prikaži ovu nit -
Endpoints'
@JohnCendpts writes on$MRK's plans to lay off about 200 of the 584 workers in Riom, France https://bit.ly/32Dfka5 Merck's workforce has shrunk in the past decade despite great financial success. Made this chart last month after news of 500 US layoffs:pic.twitter.com/SgkqICrZP6
-
$GWPH continues Epidiolex launch with quarter-over-quarter growth. Q3 sales of $86.1M, making it $188M YTD.pic.twitter.com/0V3E08bqmc
-
This individual patient-level variability figures to be a major part of
$AMRN's argument:pic.twitter.com/C0khbd9fvC
Prikaži ovu nit -
WaPo going with the speak-it-into-existence stylepic.twitter.com/nhFJiUnvsA
-
Fascinating panel starting on antibiotic resistance and the lack of pharma engagement. Featuring
@coukell, NICE’s Nick Crabb,@IAVI’s Mark Feinberg, US Adult CF Foundation’s Ella Balasa, Wellcome Trust’s Jeremy Knox and@Merck’s Jenelle Krishnamoorthy#MIHealthSummitpic.twitter.com/57L5Ft9CUj
Prikaži ovu nit -
Top BioPharma employers list out from Science: top 3 is
$ALNY$REGN and$INCY Here’s the top 20:pic.twitter.com/FCGyTbIW4E
Prikaži ovu nit -
A tale of big pharma over the past decade: Merck stock up ~125% Headcount down 31% from 100k to 69k More layoff plans announced today for
$MRK: https://bit.ly/2VSBcN3 pic.twitter.com/bOznnB3ZjI
-
Q3 report from
@GoodRx: average list price dropped by 0.6% in Q3, but 125 list prices were hiked in the quarter Here's the org's long-term list price index and full report here: https://www.goodrx.com/blog/wp-content/uploads/2019/10/Q3-2019-2.pdf …pic.twitter.com/vWbIHaGHit
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.